This page has not been approved by the PsychonautWiki administrators.
|Summary sheet: EPT|
|Molecular structure of EPT|
|Routes of Administration|
Early reports have characterized the effects of EPT as mild and indistinct compared to structurally similar base tryptamines such as DMT, DET and DPT, all of which are highly powerful psychedelics. Of these, it is reported to be most similar to DPT, albeit less potent and with a more manageable headspace. It remains to be seen how it behaves across the full spectrum of active doses.
Very little data exists about the pharmacological properties, metabolism, and toxicity of EPT. It has no history of human use before being sold online as a designer drug in 2016. It is either used recreationally or for research purposes.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legality
- 6 See also
- 7 External links
- 8 References
EPT, or N-ethyl-N-propyltryptamine, is a synthetic indole molecule of the tryptamine chemical class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. EPT features one propyl and one ethyl groups bound to the terminal amine RN of its tryptamine backbone.
Like with most psychedelic tryptamines, EPT is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from EPT's binding efficacy at the 5-HT2A receptors.
However, the role of these interactions and how they result in the psychedelic experience remain the subject of ongoing scientific investigation.
|| This subjective effect breakdown is a stub.|
As such, it may contain incomplete or wrong information and is still in progress.
You can help by expanding it.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death. The effects of EPT have not been researched as well as many other tryptamines. The following effects are drawn from a relatively limited sample size.
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational EPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because EPT is a research chemical with a very limited history of human usage.
Anecdotal evidence from people within the community who have tried EPT suggests that there are no negative health effects attributed to simply trying it by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like with most psychedelics, it is most often thought to be self-regulating.
Tolerance to the effects of EPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). EPT presents cross-tolerance with all psychedelics, meaning that after the consumption of EPT all psychedelics will have a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
Due to its relative obscurity, the possession and sale of EPT is unscheduled in most countries.
- United Kingdom - EPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.
- United States - EPT is unscheduled in the United States. It may be considered an analogue of DMT, which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e